{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,9,6]],"date-time":"2024-09-06T00:37:58Z","timestamp":1725583078978},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,9,5]],"date-time":"2024-09-05T00:00:00Z","timestamp":1725494400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,9,5]],"date-time":"2024-09-05T00:00:00Z","timestamp":1725494400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Surg Onc"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Micropapillary (MPP) adenocarcinoma is considered one of the most aggressive pathological types of lung adenocarcinoma (LADC). This retrospective study aimed to evaluate the prognostic significance and benefit of postoperative adjuvant therapy (PAT) in stage IA LADC patients with different proportions of MPP components.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Materials and methods<\/jats:title>\n                <jats:p>We retrospectively examined clinical stage IA LADC patients who underwent surgical resection between August 2012 and December 2019. In terms of the proportion of MPP components (TPM), the tumors were reclassified into three categories: MPP patterns absent (TPMN); low proportions of MPP components (TPML); and high proportions of MPP components (TPMH). The dates of recurrence and metastasis were identified based on physical examinations and were confirmed by histopathological examination.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Overall, 505 (TPMN, <jats:italic>n<\/jats:italic>\u2009=\u2009375; TPML, <jats:italic>n<\/jats:italic>\u2009=\u200992; TPMH, <jats:italic>n<\/jats:italic>\u2009=\u200938) patients harboring EGFR mutations were enrolled in the study. Male sex (<jats:italic>P<\/jats:italic>\u2009=\u20090.044), high pathological stage (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001), and MPP pathological subtype (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001) were more frequent in the TPM-positive (TPMP) group than in the TPM-negative (TPMN) group. Five-year disease-free survival (DFS) rates were significantly lower in the TPMP group than in the TPMN group (84.5% vs. 93.4%, <jats:italic>P<\/jats:italic>\u2009=\u20090.006). In addition, patients with high proportions (greater than 10%) of MPP components had worse overall survival (OS) (91.0% vs. 98.9%, <jats:italic>P<\/jats:italic>\u2009=\u20090.025) than those with low proportions (5%\u2264 TPM\u2009\u2264\u200910%). However, postoperative EGFR tyrosine kinase inhibitors (TKIs) or adjuvant chemotherapy (ACT) cannot improve DFS and OS between EGFR-mutated patients with different proportions of MPP components.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>MPP was related to earlier recurrence and shortened survival time, even in stage IA. Further research needs a larger sample size to clarify that EGFR-mutated stage IA patients with MPP components obtain survival benefits from adjuvant therapy.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12957-024-03429-y","type":"journal-article","created":{"date-parts":[[2024,9,5]],"date-time":"2024-09-05T02:01:48Z","timestamp":1725501708000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The impact of postoperative adjuvant therapy on EGFR-mutated stage IA lung adenocarcinoma with micropapillary pathological subtypes"],"prefix":"10.1186","volume":"22","author":[{"given":"Ran","family":"Cheng","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhexue","family":"Hao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiang","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sihe","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianzhao","family":"Xian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haoyang","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianfu","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhenhui","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kaiwen","family":"Ye","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wentao","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yaowen","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,9,5]]},"reference":[{"issue":"1","key":"3429_CR1","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.jtho.2015.09.009","volume":"11","author":"P Goldstraw","year":"2016","unstructured":"Goldstraw P, Chansky K, Crowley J, et al. The IASLC Lung Cancer Staging Project: proposals for revision of the TNM Stage groupings in the Forthcoming (Eighth) Edition of the TNM classification for Lung Cancer. J Thorac Oncol. 2016;11(1):39\u201351.","journal-title":"J Thorac Oncol"},{"issue":"21","key":"3429_CR2","doi-asserted-by":"publisher","first-page":"3552","DOI":"10.1200\/JCO.2007.13.9030","volume":"26","author":"JP Pignon","year":"2008","unstructured":"Pignon JP, Tribodet H, Scagliotti GV, et al. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. J Clin Oncol. 2008;26(21):3552\u20139.","journal-title":"J Clin Oncol"},{"issue":"8","key":"3429_CR3","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1001\/jama.2019.11058","volume":"322","author":"KC Arbour","year":"2019","unstructured":"Arbour KC, Riely GJ. Systemic therapy for locally Advanced and Metastatic Non-small Cell Lung Cancer: a review. JAMA. 2019;322(8):764\u201374.","journal-title":"JAMA"},{"issue":"18","key":"3429_CR4","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.1056\/NEJMoa2027071","volume":"383","author":"YL Wu","year":"2020","unstructured":"Wu YL, Tsuboi M, He J, et al. Osimertinib in Resected EGFR-Mutated non-small-cell Lung Cancer. N Engl J Med. 2020;383(18):1711\u201323.","journal-title":"N Engl J Med"},{"issue":"3","key":"3429_CR5","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1007\/s12253-017-0274-7","volume":"24","author":"JS Pyo","year":"2018","unstructured":"Pyo JS, Kim JH. Clinicopathological significance of Micropapillary Pattern in Lung Adenocarcinoma. Pathol Oncol Res. 2018;24(3):547\u201355.","journal-title":"Pathol Oncol Res"},{"issue":"1","key":"3429_CR6","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1186\/s13019-020-01199-8","volume":"15","author":"W Wang","year":"2020","unstructured":"Wang W, Hu Z, Zhao J, et al. Both the presence of a micropapillary component and the micropapillary predominant subtype predict poor prognosis after lung adenocarcinoma resection: a meta-analysis. J Cardiothorac Surg. 2020;15(1):154.","journal-title":"J Cardiothorac Surg"},{"issue":"4","key":"3429_CR7","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1002\/jso.26760","volume":"125","author":"W Huang","year":"2021","unstructured":"Huang W, Zhang H, Zhang Z, et al. A prognostic nomogram based on a new classification of combined micropapillary and solid components for stage IA invasive lung adenocarcinoma. J Surg Oncol. 2021;125(4):796\u2013808.","journal-title":"J Surg Oncol"},{"issue":"6","key":"3429_CR8","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1097\/SLA.0b013e31828920c0","volume":"258","author":"JJ Hung","year":"2013","unstructured":"Hung JJ, Jeng WJ, Chou TY, et al. Prognostic value of the new International Association for the Study of Lung Cancer\/American Thoracic Society\/European Respiratory Society lung adenocarcinoma classification on death and recurrence in completely resected stage I lung adenocarcinoma. Ann Surg. 2013;258(6):1079\u201386.","journal-title":"Ann Surg"},{"issue":"16","key":"3429_CR9","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1093\/jnci\/djt166","volume":"105","author":"J Nitadori","year":"2013","unstructured":"Nitadori J, Bograd AJ, Kadota K, et al. Impact of micropapillary histologic subtype in selecting limited resection vs lobectomy for lung adenocarcinoma of 2\u00a0cm or smaller. J Natl Cancer Inst. 2013;105(16):1212\u201320.","journal-title":"J Natl Cancer Inst"},{"issue":"6","key":"3429_CR10","doi-asserted-by":"publisher","first-page":"2310","DOI":"10.1016\/j.jtcvs.2018.07.054","volume":"156","author":"ZR Zhao","year":"2018","unstructured":"Zhao ZR, Lau RWH, Long H, et al. Novel method for rapid identification of micropapillary or solid components in early-stage lung adenocarcinoma. J Thorac Cardiovasc Surg. 2018;156(6):2310\u2013e23182312.","journal-title":"J Thorac Cardiovasc Surg"},{"issue":"2","key":"3429_CR11","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1111\/1759-7714.13754","volume":"12","author":"SH Choi","year":"2021","unstructured":"Choi SH, Jeong JY, Lee SY, et al. Clinical implication of minimal presence of solid or micropapillary subtype in early-stage lung adenocarcinoma. Thorac Cancer. 2021;12(2):235\u201344.","journal-title":"Thorac Cancer"},{"issue":"5","key":"3429_CR12","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1007\/s11748-017-0747-3","volume":"65","author":"Y Yoshida","year":"2017","unstructured":"Yoshida Y, Nitadori JI, Shinozaki-Ushiku A, et al. Micropapillary histological subtype in lung adenocarcinoma of 2\u00a0cm or less: impact on recurrence and clinical predictors. Gen Thorac Cardiovasc Surg. 2017;65(5):273\u20139.","journal-title":"Gen Thorac Cardiovasc Surg"},{"issue":"4","key":"3429_CR13","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1007\/s00432-017-2571-7","volume":"144","author":"Y Yuan","year":"2018","unstructured":"Yuan Y, Ma G, Zhang Y, Chen H. Presence of Micropapillary and solid patterns are associated with nodal upstaging and unfavorable prognosis among patient with cT1N0M0 lung adenocarcinoma: a large-scale analysis. J Cancer Res Clin Oncol. 2018;144(4):743\u20139.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"3","key":"3429_CR14","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1016\/j.jtcvs.2017.09.143","volume":"155","author":"F Qian","year":"2018","unstructured":"Qian F, Yang W, Wang R, et al. Prognostic significance and adjuvant chemotherapy survival benefits of a solid or micropapillary pattern in patients with resected stage IB lung adenocarcinoma. J Thorac Cardiovasc Surg. 2018;155(3):1227\u2013e12351222.","journal-title":"J Thorac Cardiovasc Surg"},{"issue":"3","key":"3429_CR15","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1002\/cncr.26311","volume":"118","author":"HR Kim","year":"2012","unstructured":"Kim HR, Shim HS, Chung JH, et al. Distinct clinical features and outcomes in never-smokers with nonsmall cell lung cancer who harbor EGFR or KRAS mutations or ALK rearrangement. Cancer. 2012;118(3):729\u201339.","journal-title":"Cancer"},{"issue":"12","key":"3429_CR16","doi-asserted-by":"publisher","first-page":"1815","DOI":"10.1097\/JTO.0b013e31826bb7b2","volume":"7","author":"SP D\u2019Angelo","year":"2012","unstructured":"D\u2019Angelo SP, Janjigian YY, Ahye N, et al. Distinct clinical course of EGFR-mutant resected lung cancers: results of testing of 1118 surgical specimens and effects of adjuvant gefitinib and erlotinib. J Thorac Oncol. 2012;7(12):1815\u201322.","journal-title":"J Thorac Oncol"},{"issue":"6","key":"3429_CR17","doi-asserted-by":"publisher","first-page":"e213","DOI":"10.1016\/j.cllc.2015.04.005","volume":"16","author":"Y Kudo","year":"2015","unstructured":"Kudo Y, Shimada Y, Saji H, et al. Prognostic factors for Survival after recurrence in patients with completely resected lung adenocarcinoma: important roles of epidermal growth factor receptor mutation status and the current staging system. Clin Lung Cancer. 2015;16(6):e213\u2013221.","journal-title":"Clin Lung Cancer"},{"issue":"2","key":"3429_CR18","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1097\/JTO.0b013e318160c607","volume":"3","author":"JL Marks","year":"2008","unstructured":"Marks JL, Broderick S, Zhou Q, et al. Prognostic and therapeutic implications of EGFR and KRAS mutations in resected lung adenocarcinoma. J Thorac Oncol. 2008;3(2):111\u20136.","journal-title":"J Thorac Oncol"},{"issue":"1","key":"3429_CR19","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1097\/JTO.0b013e3181914111","volume":"4","author":"T Kosaka","year":"2009","unstructured":"Kosaka T, Yatabe Y, Onozato R, Kuwano H, Mitsudomi T. Prognostic implication of EGFR, KRAS, and TP53 gene mutations in a large cohort of Japanese patients with surgically treated lung adenocarcinoma. J Thorac Oncol. 2009;4(1):22\u20139.","journal-title":"J Thorac Oncol"},{"issue":"12","key":"3429_CR20","doi-asserted-by":"publisher","first-page":"1594","DOI":"10.1111\/1759-7714.12866","volume":"9","author":"M Ito","year":"2018","unstructured":"Ito M, Miyata Y, Kushitani K, et al. Increased risk of recurrence in resected EGFR-positive pN0M0 invasive lung adenocarcinoma. Thorac Cancer. 2018;9(12):1594\u2013602.","journal-title":"Thorac Cancer"},{"issue":"12","key":"3429_CR21","doi-asserted-by":"publisher","first-page":"1772","DOI":"10.1097\/JTO.0000000000000341","volume":"9","author":"Y Zhang","year":"2014","unstructured":"Zhang Y, Wang R, Cai D, et al. A comprehensive investigation of molecular features and prognosis of lung adenocarcinoma with micropapillary component. J Thorac Oncol. 2014;9(12):1772\u20138.","journal-title":"J Thorac Oncol"},{"issue":"6","key":"3429_CR22","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1038\/modpathol.3800780","volume":"20","author":"H Tsutsumida","year":"2007","unstructured":"Tsutsumida H, Nomoto M, Goto M, et al. A micropapillary pattern is predictive of a poor prognosis in lung adenocarcinoma, and reduced surfactant apoprotein A expression in the micropapillary pattern is an excellent indicator of a poor prognosis. Mod Pathology: Official J United States Can Acad Pathol Inc. 2007;20(6):638\u201347.","journal-title":"Mod Pathology: Official J United States Can Acad Pathol Inc"},{"issue":"1","key":"3429_CR23","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.lungcan.2013.04.003","volume":"81","author":"S Sumiyoshi","year":"2013","unstructured":"Sumiyoshi S, Yoshizawa A, Sonobe M, et al. Pulmonary adenocarcinomas with micropapillary component significantly correlate with recurrence, but can be well controlled with EGFR tyrosine kinase inhibitors in the early stages. Lung Cancer. 2013;81(1):53\u20139.","journal-title":"Lung Cancer"},{"issue":"5","key":"3429_CR24","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1309\/AJCPBS85VJEOBPDO","volume":"131","author":"OD De Achcar","year":"2009","unstructured":"De Achcar OD, Nikiforova R, Yousem MN. Micropapillary lung adenocarcinoma: EGFR, K-ras, and BRAF mutational profile. Am J Clin Pathol. 2009;131(5):694\u2013700.","journal-title":"Am J Clin Pathol"},{"issue":"2","key":"3429_CR25","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1097\/JTO.0b013e3182381515","volume":"7","author":"PL Sun","year":"2012","unstructured":"Sun PL, Seol H, Lee HJ, et al. High incidence of EGFR mutations in Korean men smokers with no intratumoral heterogeneity of lung adenocarcinomas: correlation with histologic subtypes, EGFR\/TTF-1 expressions, and clinical features. J Thorac Oncol. 2012;7(2):323\u201330.","journal-title":"J Thorac Oncol"},{"issue":"3","key":"3429_CR26","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1007\/s00595-013-0589-2","volume":"44","author":"T Ohba","year":"2014","unstructured":"Ohba T, Toyokawa G, Kometani T, et al. Mutations of the EGFR and K-ras genes in resected stage I lung adenocarcinoma and their clinical significance. Surg Today. 2014;44(3):478\u201386.","journal-title":"Surg Today"},{"issue":"5","key":"3429_CR27","doi-asserted-by":"publisher","first-page":"497","DOI":"10.6004\/jnccn.2022.0025","volume":"20","author":"DS Ettinger","year":"2022","unstructured":"Ettinger DS, Wood DE, Aisner DL, et al. Non-small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice guidelines in Oncology. J Natl Compr Cancer Network: JNCCN. 2022;20(5):497\u2013530.","journal-title":"J Natl Compr Cancer Network: JNCCN"},{"issue":"6","key":"3429_CR28","doi-asserted-by":"publisher","first-page":"2051","DOI":"10.1245\/s10434-019-08113-0","volume":"27","author":"C Wang","year":"2020","unstructured":"Wang C, Yang J, Lu M. Micropapillary Predominant Lung Adenocarcinoma in Stage IA benefits from Adjuvant Chemotherapy. Ann Surg Oncol. 2020;27(6):2051\u201360.","journal-title":"Ann Surg Oncol"},{"issue":"1","key":"3429_CR29","doi-asserted-by":"publisher","first-page":"64","DOI":"10.21037\/tlcr-21-934","volume":"11","author":"Y Hou","year":"2022","unstructured":"Hou Y, Song W, Chen M, et al. The presence of lepidic and micropapillary\/solid pathological patterns as minor components has prognostic value in patients with intermediate-grade invasive lung adenocarcinoma. Transl Lung Cancer Res. 2022;11(1):64\u201374.","journal-title":"Transl Lung Cancer Res"}],"container-title":["World Journal of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12957-024-03429-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12957-024-03429-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12957-024-03429-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,5]],"date-time":"2024-09-05T02:02:18Z","timestamp":1725501738000},"score":1,"resource":{"primary":{"URL":"https:\/\/wjso.biomedcentral.com\/articles\/10.1186\/s12957-024-03429-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,5]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["3429"],"URL":"https:\/\/doi.org\/10.1186\/s12957-024-03429-y","relation":{},"ISSN":["1477-7819"],"issn-type":[{"value":"1477-7819","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,5]]},"assertion":[{"value":"21 November 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 May 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 September 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The retrospective study was approved by the Ethics Committee of the National Center for Respiratory Medicine\/The First Affiliated Hospital of Guangzhou Medical University (Date May 16th, 2022; IRB number: 2022 NO.71). Informed consent was waived due to the retrospective nature of the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics declarations & trial registry information"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"235"}}